Key Highlights

  • Pre-market quote of USD 2.07 on November 4, 2026, a USD 0.2412 rise from the Tuesday close
  • Cash and marketable securities stood at USD 148.8 million on June 30, 2026, compared with USD 201.7 million on December 31, 2025
  • The second quarter of 2026 produced a net loss of USD 24.5 million, or USD 0.40 a share, compared with USD 33.4 million a year before
  • Management guides to tau PET data for VY7523 and first VY1706 dosing, both in the fourth quarter of 2026
  • The company expects its cash runway to extend into 2028

Voyager Therapeutics Price Action Before the Open (up USD 0.2412, 13.19%)

Voyager Therapeutics (NASDAQ:VYGR) traded 13.19% higher at USD 2.07 in pre-market trading on November 4, 2026, a USD 0.2412 advance on the Tuesday, November 3 close of about USD 1.83 (calculated). The clinical-stage firm builds tau-targeting antibodies and gene therapies aimed at Alzheimer's disease.

No Voyager press release, company filing or trial readout dated November 2 to November 4, 2026 could be found, so the move cannot be linked to a company announcement. Partner Neurocrine Biosciences (NASDAQ:NBIX) reported third quarter 2026 results on November 3, with Revenue of USD 1.12 billion, adjusted Earnings of USD 3.29 a share and a higher full-year revenue outlook of USD 2.9 billion to USD 2.925 billion. That release did not concern Voyager, although it may have drawn attention to businesses linked to its pipeline.

Upcoming Milestones From Management Guidance

VY7523 is an anti-tau antibody under study in a randomized, placebo-controlled, phase 1/2 multiple ascending dose trial in early Alzheimer's disease. Tau PET imaging, an exploratory endpoint measured at 6 and 12 months, is expected in the fourth quarter of 2026. An earlier single ascending dose study in 48 healthy adults met its primary safety goal, with no serious or severe adverse events and a cerebrospinal fluid to serum ratio of 0.3%.

VY1706 is a one-time intravenous gene therapy that delivers an siRNA targeting the MAPT gene through the company's TRACER capsid. The FDA cleared the IND in June 2026, and Health Canada cleared a clinical trial application in July 2026. In nonhuman primates, tau protein dropped 48% to 64% at 13 weeks, with reductions of up to 75% held through six months. First dosing is guided for the fourth quarter of 2026, with initial safety data expected in early 2027.

Neurocrine plans to begin a trial of NBIB-'223 for Friedreich's ataxia in the second half of 2026, subject to FDA IND clearance.

Financial Position and Key Risks

The second quarter 2026 release dated August 6, 2026 showed Voyager collaboration revenue of USD 3.2 million, down from USD 5.2 million a year earlier. Research and Development expenses declined to USD 22.0 million from USD 31.3 million, while general and administrative expenses dropped to USD 7.5 million from USD 10.5 million. The net loss narrowed to USD 24.5 million, or USD 0.40 a share, from USD 33.4 million, or USD 0.57 a share.

Cash and marketable securities totaled USD 148.8 million on June 30, 2026, a decline of USD 52.9 million from year end (calculated). The company said this supports operations into 2028. With the stock at USD 2.07, below USD 5, investors face volatility, thin Liquidity and dilution risk from any future Equity raise, and trial results could move the shares sharply in either direction.

Key Items to Monitor

The main dates are the fourth quarter 2026 tau PET readout for VY7523 and the first patient dosing for VY1706. The timing of the third quarter financial update and any news on the Neurocrine IND will also count, along with whether the pre-market gain holds once regular trading opens.